Stock Market Update - September 24, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. APUS - Apimeds Pharmaceuticals US, Inc
Price: $4.92 | Change: +114.85% ($2.63)
APUS skyrocketed by an impressive 114.85% around September 25, 2026, thanks to a major new technology services agreement involving its wholly-owned subsidiary, MindWave Innovations Inc. MindWave announced a 12-month deal with Singapore-based AQUAE Holdings to develop and operate AQUAEChain, a new platform designed to manage digital conservation credits.
MindWave will use its specialized MindChain technology to build and support AQUAEChain. In return, it will receive service fees and a recurring share of these conservation credits. This initial agreement also includes an option for a five-year extension, signaling potential for a long-term partnership.
This deal represents a significant commercial expansion for MindWave's digital asset business, especially as it comes just before the anticipated launch of its core MindChain platform in October. Investors clearly saw this partnership as a strong indicator of MindWave's growing presence in the digital asset space.
2. SRZN - Surrozen, Inc.
Price: $33.68 | Change: +108.42% ($17.52)
SRZN recorded an impressive 108.42% gain around late September 2026. This substantial climb was largely driven by Surrozen, Inc.'s submission of an Investigational New Drug (IND) application to the FDA for SZN-8141. This critical regulatory step means the company can now advance its lead candidate, a potential new treatment for diabetic macular edema (DME), into clinical trials.
SZN-8141 stands out due to its innovative dual-mechanism approach. It's designed to activate the Wnt pathway while also inhibiting VEGF within a single molecule. Surrozen believes this combined action can uniquely address vascular leakage and support overall retinal vascular health, potentially offering an advantage over existing therapies. The company aims to begin its first human trial by the end of 2026, with initial data anticipated in the second half of 2027.
This positive pipeline development, coupled with better-than-expected second-quarter financial results and analyst upgrades, generated significant investor interest. It’s a compelling example of how a key regulatory milestone can significantly impact a biotechnology stock.
3. GLND - Greenland Energy Company Common Stock
Price: $5.35 | Change: +83.85% ($2.44)
GLND jumped a massive 83.85% around September 25, 2026. This significant surge came after Greenland Energy Company announced an amendment to its farm-out agreement with 80 Mile plc. The core of the deal: extended deadlines for two crucial exploration wells in East Greenland's Jameson Land Basin, pushing them out to December 31, 2028.
Essentially, this gives GLND vital extra time to secure the necessary permits and approvals for drilling, a common hurdle in exploration-stage projects. While GLND will now handle these permitting costs and pay a £500,000 fee, investors viewed this strategic move as significantly reducing near-term execution risk. This kind of clarity and extended timeline is particularly valuable for exploration-stage companies seeking to advance their projects.
4. PMAX - Powell Max Limited Class A Ordinary Shares
Price: $1.65 | Change: +80.62% ($0.7365)
PMAX saw an impressive 80.62% gain on NASDAQ around late September 2026. This significant jump, however, didn't come with a clear explanation. A review of news and corporate announcements around that time, including for a daily high of +76.9% on September 23rd, revealed no specific catalysts.
There were no reported partnerships, financial results, or other typical market-moving events to justify such a dramatic increase. While Powell Max, a Hong Kong-based financial communications provider, had earlier completed a share consolidation and corporate repositioning, these events took place months before the late September surge. What makes PMAX's sudden rise particularly noteworthy is the absence of an identifiable reason for the spike, especially considering analyst sentiment around the same period generally rated the stock as a "Sell."
5. STAK - STAK Inc. Ordinary Shares
Price: $1.44 | Change: +53.19% ($0.5)
STAK saw an impressive 53.19% gain recently, with shares surging around September 25, 2026. This significant jump appears to be fueled by renewed investor excitement and a technical rebound surrounding the company's previously announced plans for an AI-ready distributed power solutions subsidiary.
Back in June, STAK Inc. revealed plans to form a majority-owned U.S. subsidiary focused on developing modular gas-to-electricity power generation systems specifically designed for energy-hungry artificial intelligence data centers across North America. While this news initially boosted the stock by 20% in June, recent market activity shows investors are still heavily focused on the long-term potential of this move into AI-focused energy solutions.
It's worth noting that STAK has experienced considerable ups and downs, including a sharp drop after a massive rally earlier in July. So, this latest climb likely reflects a renewed positive outlook and a technical bounce as the market continues to assess how much this AI power venture could drive future growth for STAK Inc.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.